BioFilm Pharma

BioFilm Pharma is a Pharmaceutical startup established in 2017, dedicated to revolutionizing the treatment of chronic diseases, particularly diabetic foot ulcers. With a focus on addressing the significant annual influx of new patients, estimated at 15 million, the company aims to alleviate the substantial 4 billion € burden on high-income country healthcare systems. Their groundbreaking approach involves the development of first-in-class products capable of both preventing and curing biofilm-related infections, representing a paradigm shift in antibiotherapy. Currently, BioFilm Pharma boasts a pipeline of 5 compounds and anticipates achieving proof-of-concept in patients within the next 3 years, potentially yielding blockbuster products.

Having already secured 2.4 M€ from a syndicate of historic investors and grants, the company now seeks 20 M€ in additional funding to facilitate the progression of CMC, preclinical, and clinical studies. This step is pivotal in driving the innovative technology toward commercialization, ultimately reinforcing the company's position as a key player in the pharmaceutical industry. As BioFilm Pharma prepares to embark on this crucial phase, the potential for growth and impact within the healthcare sector is tangible, positioning the company as an attractive prospect for venture capital investors seeking to support groundbreaking solutions in pharmaceutical innovation.